Concord Biotech · NSE: CONCORDBIO · BSE: 543960
Q2 FY25 results · Jul–Sep 2024
Concord Biotech reported revenue from operations of ₹310.18 crore (up 18.2% from Q2 FY24) and net profit of ₹95.74 crore (up 18.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.18 | 262.35 | +18.2% | 215.80 | +43.7% |
| Other income | 10.03 | 8.13 | +23.4% | 10.31 | −2.7% |
| Total income | 320.21 | 270.47 | +18.4% | 226.11 | +41.6% |
| Profit before share of associates & JVs and tax | 133.29 | 113.18 | +17.8% | 78.17 | +70.5% |
| Share of profit/(loss) of associates & JVs | (2.96) | (3.47) | 1.35 | ||
| Net profit for the period | 95.74 | 81.02 | +18.2% | 59.59 | +60.7% |
| EPS, basic (₹) | 9.15 | 7.74 | +18.2% | 5.70 | +60.5% |
| Net margin (%) | 30.9 | 30.9 | 27.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 310.18 | 262.35 | +18.2% | 215.80 | +43.7% |
| Other income | 10.03 | 8.13 | +23.4% | 10.31 | −2.7% |
| Total income | 320.21 | 270.47 | +18.4% | 226.11 | +41.6% |
| Profit before tax | 133.29 | 113.18 | +17.8% | 78.17 | +70.5% |
| Net profit for the period | 98.70 | 84.49 | +16.8% | 58.24 | +69.5% |
| EPS, basic (₹) | 9.43 | 8.08 | +16.8% | 5.57 | +69.3% |
| Net margin (%) | 31.8 | 32.2 | 27.0 |
Consolidated
- Filed with BSE
- 12 Nov 2024, 10:50 IST
- Board meeting
- 11 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 Nov 2024, 10:50 IST
- Board meeting
- 11 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE